An interview with Ann Becker Schutte, Ph.D Last year, for the first time, I attended Stanford...READ MORE
Russell Budd of Baron and Budd Appointed to Plaintiffs’ Steering Committee in Transvaginal Mesh Litigation
Thousands of Lawsuits Still Pending in Transvaginal Mesh Litigation
DALLAS –(May 6, 2014) –Russell Budd, co-founder and managing shareholder of Baron and Budd, has been appointed to serve on the Plaintiffs’ Steering Committee (PSC) in the litigation surrounding issues with the transvginal mesh implant. This committee oversees all activity in the litigation on the plaintiffs’ side, meaning that Budd will take an active role in the protecting the rights of every woman who has filed a lawsuit regarding transvaginal mesh issues.
On April 3, a Dallas jury awarded a mesh patient $1.2 million after suffering serious health problems from her transvaginal mesh implant. The jury also found transvaginal mesh manufacturer Ethicon and its parent company Johnson & Johnson responsible for defects related to their TVT-O transvaginal mesh sling. Other mesh lawsuits are ongoing and Baron & Budd currently represents hundreds of women nationwide.
"The effects of this mesh have been devastating for so many women who went into routine surgery only to find themselves facing a lifetime of pain. We hope to send a clear message to the makers of this mesh that it was wrong to push this product on doctors and female patients without proper study," says Russell Budd."Our women’s pharmaceutical team is determined to help bring about justice."
Baron and Budd is a leader in national pharmaceutical litigation. In addition to transvaginal mesh, the firm is currently assisting people who have been harmed by fluoroquinolones such as Levaquin and Cipro; dialysis products GranuFlo/NaturaLyte; Risperdal, Testosterone therapy products such as AndroGel; and others. To learn more about transvaginal mesh or any other pharmaceutical product please call 866-520-2755 or contact us here.
The law firm of Baron and Budd has a more than 35-year history of protecting the rights of consumers and spearheading signification litigation on a national scale. Firm shareholders currently serve on the Plaintiffs’ Steering Committee in the GranuFlo/NaturaLyte litigation. Baron and Budd also represents numerous states in lawsuits regarding the deceptive marketing of diabetes drug Avandia, as well as thousands of patients harmed by the drug.